Urine Drug Testing Fraud: The Panel, the Frequency and the Referral

Urine drug testing fraud includes knowingly billing for unnecessary tests, overstating the testing performed and buying referrals with money or free services. The result can be accurate while the claim rests on a test the patient never needed. Taxpayers pay for the excess testing. For someone inside a laboratory, pain clinic or treatment program, the revealing detail may be a panel that never changes, a confirmation ordered before anyone reads the screen, or a sales agreement that rewards more testing. The machine answers what is in the specimen. The order, patient chart and bill explain why the government was asked to pay.

Presumptive and Definitive Testing Answer Different Questions

Presumptive urine drug testing screens for the presence or absence of drugs or drug classes. Definitive testing identifies particular substances and, where applicable, their concentrations. Those different jobs matter when a laboratory sells both together.

The clinical distinction appears throughout Urine drug screening: A guide to monitoring Tx with controlled substances, published in the Journal of Family Practice in 2021. The review explains that immunoassays can produce false positives and false negatives, and that the clinical question should guide the choice of test. More specific confirmation testing can help resolve an unexpected screen. The patient’s history and treatment explain why that additional test is needed.

An automatic pair of tests removes that decision. If confirmation is already running before the screen returns, the screening result cannot explain why that confirmation was ordered. A broad panel selected once can repeat that choice across an entire practice.

In Labcorp’s July 2026 settlement, the company agreed to pay $14.5 million to resolve allegations of medically unnecessary Medicare urine testing. It admitted that its ToxAssure Comprehensive panel combined presumptive testing for some substances with direct-to-definitive testing for others. Many tests ran simultaneously on the same patient’s sample, on the same date.

Labcorp admitted billing the all-inclusive presumptive code and the highest-tier definitive code each time it performed that panel. The government alleged that the resulting claims were medically unnecessary. The product being sold had already joined the testing decisions together.

When Are Toxicology Tests Unnecessary?

Toxicology tests are unnecessary when their scope or frequency lacks a patient-specific clinical reason, or when they serve a nonmedical monitoring requirement rather than diagnosis or treatment. The patient’s medication, history, earlier results and treatment needs belong behind the order.

The Journal of Family Practice review recommends risk-based frequency for patients prescribed controlled substances. In addiction treatment, it describes testing that becomes less frequent as the patient’s condition improves. It also makes a point that a fixed testing schedule can miss:

For an insider examining repeated bills, it makes the treatment record consequential: did the patient’s changing condition change the testing, or did the same panel keep arriving with each specimen?

The whistleblower complaint involving Logan Laboratories alleged that physician authorizations kept a preset panel running:

The same complaint alleged that the electronic medical record system automatically coupled a drug screen with confirmation testing for all patients and restricted laboratory choice. The allegation reaches the software and the original authorization, well before the claim.

In April 2020, the Justice Department announced a $41 million settlement across Logan, Tampa Pain Relief Centers and two former executives. The government alleged unnecessary urine testing billed to Medicare, Medicaid, TRICARE and other federal health care programs. The department said the whistleblowers would receive approximately $7.79 million.

Do Doctors Get Kickbacks for Ordering Tests?

Yes, according to the government’s cases: laboratories have been accused of giving doctors free testing supplies and other benefits in exchange for referrals. The value can be something the practice would otherwise buy: a test cup, staff time, equipment or services.

Millennium Health’s 2015 resolution included $227 million for urine drug testing allegations. The government alleged medically unnecessary testing and free point-of-care cups for physicians who agreed to refer testing. The cup gave the practice an immediate benefit. The referral gave the laboratory more testing to bill.

These cups can do more than hold urine. A dual-use cup produces an on-site result and supplies a specimen for further laboratory testing. In its laboratory payments fraud alert, the Department of Health and Human Services’ Office of Inspector General specifically identified free or below-market cups used by referring providers to perform billable office testing.

Free labor can serve the same commercial purpose. A competitor’s complaint against Ameritox and other laboratories alleged that Ameritox supplied free specimen-collection personnel to physician offices to induce referrals. The practice’s staffing benefit and the laboratory’s specimen volume belonged in the same transaction.

The paid-referral chain can also reach the person entering the order. In its account of the criminal trial involving Spectra Clinical Labs, the Justice Department described evidence that the operator paid marketers a percentage of Medicare reimbursements through marketing companies he secretly controlled. The marketers trained doctors’ office staff to send orders for expensive panels that the doctors did not want or authorize.

That criminal trial evidence shows why the referral inquiry reaches beyond a physician’s signature. The marketer’s pay formula, the staff training and the order sent to the laboratory can explain how the highest-paying panel became the routine one.

Standing Orders and Custom Profiles Put the Decision on the Form

A physician-directed conditional order ties additional testing to a result specified by the treating practitioner. A laboratory protocol can instead make the additional test automatic. The difference appears in who selected the condition and what the patient’s order actually says.

Medicare’s ordering guidance describes a practitioner requesting an additional test if the initial result meets a specified condition. The treating clinician also holds the patient record that explains the medical need. The laboratory receives the order, performs the work and submits the claim. Those records live on different sides of the business relationship.

Precision Toxicology, which operates as Precision Diagnostics, agreed to a $27 million settlement in October 2024. The government alleged that its custom profiles functioned as standing orders, producing large test menus without an individualized assessment. The allegations also included free items supplied to physicians who referred expensive testing. The alleged profile set the volume. The alleged free items helped deliver it.

The industry’s own compliance literature has long treated the requisition as a control. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described standardized offerings, uniform requisitions and physician acknowledgement of custom profiles. It also described monitoring standing orders for continued validity.

That historical account points to records an insider will recognize: the blank form given to every new client, the profile selected for the practice and the renewal of an old authorization. The question is how those documents reflect the individual patient’s need for the testing being billed.

Precision’s integrity agreement required review of client registrations, requisitions or order forms, and applicable test results to identify patterns inconsistent with medically necessary testing. The review reaches back to where the tests were selected.

The Billing Code Describes Work the Laboratory Must Support

The code on a urine-testing claim describes the type and extent of testing billed. A mismatch can involve the method, the number of drug classes or the units charged.

Medicare’s presumptive codes are 80305 through 80307. Definitive codes G0480 through G0483 rise with the number of drug classes tested, from one through seven at the first tier to 22 or more at the highest. Labcorp’s admitted simultaneous billing used 80307 and G0483. Those codes tell a billing employee which services the panel was being presented as providing.

The class count deserves its own comparison with the performed work. In the Bluewater Toxicology settlement, the government alleged claims for the highest class tier when fewer classes were tested, along with insufficient documentation of the treating physician’s intent to order the billed test. The order and the method had to support the claim’s description of the service.

LabTox’s 2019 civil settlement addressed a different mismatch: allegations that it billed high-complexity urine testing while using a low-complexity method, and billed specimen-validity testing. The test result alone would not reveal that difference. The laboratory’s method and the claim would.

The inspector general’s administrative settlement with Medicus Laboratories concerned allegations of excessive units of urine testing and medically unnecessary screening. A biller comparing the units charged with the work performed may see a pattern that a clinician reading a result would never see.

Coverage also varies by Medicare contractor. In a 2021 audit, the inspector general found inconsistent contractor requirements for counting drug classes, controlling testing frequency and identifying direct-to-definitive testing. Which contractor’s rule applied is one of the questions we work through with you.

Can Specimen Validity Testing Be Billed Separately?

Specimen validity testing performed as quality control with urine drug testing is not separately payable as a Medicare benefit. Creatinine, pH and other checks used to assess the specimen belong to that billing question.

These checks have a practical purpose. Dilution, adulteration and substitution can affect what a urine test reports. The Journal of Family Practice review describes collection controls and testing for pH, creatinine and adulterants as ways to identify interference. The collection record and the validity result help explain the specimen the laboratory actually analyzed.

The billing question follows the purpose of that work. A creatinine measurement used to check a urine specimen’s validity is doing quality-control work for the drug test. When the laboratory adds a separate charge for that check, the claim presents another service for payment. LabTox’s earlier civil settlement shows why the validity work belongs beside the drug-testing claim in the review.

Court and Residential Monitoring Billed as Medical Care

Nonmedical urine testing becomes a healthcare billing issue when a laboratory presents court compliance or residential monitoring as patient treatment. The purpose of the test, who ordered it and who used the result are central.

In a later criminal case involving LabTox, the owner’s guilty plea admitted billing Medicare and Kentucky Medicaid for medically unnecessary testing, including court-ordered tests used in judicial proceedings. That admission concerned the reason for testing, distinct from the earlier civil allegations about method complexity and validity charges.

A whistleblower complaint involving Blue Waters Assessment & Testing Services alleged that court-compliance tests were neither ordered nor reviewed by treating medical professionals. It described a confirmation schedule detached from the screening result:

The complaint alleged a sham clinical relationship used to bill Kentucky Medicaid. Its account connects the intake paperwork, the monitoring purpose and the automatic confirmation order.

Residential monitoring appears in the GENCO LAB settlement allegations as well. The government alleged urine tests performed solely for monitoring beneficiaries in sober homes, along with duplicative testing. A facility requirement can generate a steady stream of specimens while the medical reason for billing each test remains missing.

A Test Already Paid for in the Treatment Bundle

Urine testing can also generate an improper claim when the treatment payment already includes it. The issue is a second payment for the same service.

Pacific Toxicology Laboratories agreed to a civil settlement over separately billing for testing of opioid treatment program patients. The government alleged that the practice caused Medicare to pay twice for urine testing for certain patients with opioid use disorder.

For an insider in a treatment program or its laboratory, the useful connection is between the treatment payment and the separate laboratory bill. The test can have a clinical purpose while the second claim asks Medicare to pay again.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects the patient’s need, the order, the performed test, the claim and the referral arrangement. It can show where a clinical decision became a repeated billing instruction.

An ordering clinician sees whether the panel reflects the patient’s treatment. Office staff see the preselected form and the instructions for sending specimens. Laboratory personnel know the method and the work performed. Billing employees see the codes, units and payer. Sales staff see what the practice receives for directing that work to the laboratory.

An automatically inserted diagnosis code can make a bill look supported when the ordering clinician supplied no diagnostic information.

We work through those connections with insiders. A standing authorization beside repeated claims, a method that differs from the billed service, or a commission tied to expensive panels can explain much more than an unusually large bill. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Panel Was Chosen Before the Patient

If you know how a laboratory’s panels, standing orders or referral payments became repeated claims, talk to our whistleblower experts about the testing you see from inside. We work with you to build the case around those decisions and bring in laboratory fraud whistleblower lawyers who understand toxicology billing. We stay with you through the process, focused on your strongest urine drug testing whistleblower case.